pharmaceuticals

pharmaceuticals Articles

The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. (NASDAQ: BIIB) suffered handily with the announcement that it and...
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
AbbVie and patients suffering from multiple myeloma have seen some additional bad news from the FDA.
Johnson & Johnson shares dipped on Thursday on news that a California jury awarded $29 million to a woman that claimed its talcum-powder-based products caused her cancer.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.
Abstracts have been released for the companies presenting at the American Association for Cancer Research annual meeting, and Wedbush has some ideas for what the big movers could be.
The February 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Clementia Pharmaceuticals has entered into an agreement to be acquired by French pharmaceutical company Ipsen.
Voyager Therapeutics shares made an incredible gain on Friday after the firm announced a collaboration with pharma giant AbbVie.
Here are five top health care stocks that recently saw their 50-day moving average cross below the 200-day average, a death cross.
Immune Design shares absolutely exploded on Thursday after Merck announced that it would be acquiring the firm at what some might call a ridiculous premium
For more than half a decade, the United States has seen an incredible rise of an opioid epidemic within its borders. According to a recent study, drug makers and federal regulators are the ones to...